Editorial: Application of PKPD modeling in drug discovery and development.
作者信息
Ren Hong-Can, Zhu Xiao, Hao Kun, Le Si-Yuan
机构信息
Department of Drug Metabolism and Toxicity, Shanghai Pharmaceuticals Holding Co Ltd, China.
Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, China.
出版信息
Front Pharmacol. 2025 Jun 26;16:1614689. doi: 10.3389/fphar.2025.1614689. eCollection 2025.
Abstract
摘要
相似文献
1
Editorial: Application of PKPD modeling in drug discovery and development.社论：药代动力学-药效学（PKPD）模型在药物研发中的应用
Front Pharmacol. 2025 Jun 26;16:1614689. doi: 10.3389/fphar.2025.1614689. eCollection 2025.
2
Model-informed Drug Development (MIDD) Approach to Support Biopharmaceutical Development of Iberdomide.基于模型的药物开发（MIDD）方法支持艾伯多米德的生物制药开发。
AAPS J. 2025 Apr 29;27(4):85. doi: 10.1208/s12248-025-01071-4.
3
Considerations for Regulatory Reusability of Dynamic Tools in the New Drug Development.新药研发中动态工具的监管可复用性考量
Pharm Res. 2025 Mar 4. doi: 10.1007/s11095-025-03831-5.
4
Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.基于生理的药代动力学（PBPK）建模与模拟方法：对已发表模型、应用及模型验证的系统综述
Drug Metab Dispos. 2015 Nov;43(11):1823-37. doi: 10.1124/dmd.115.065920. Epub 2015 Aug 21.
5
Sialic Acid Mediated Endothelial and Hepatic Uptake: A Mechanism based Mathematic Model Elucidating the Complex Pharmacokinetics and Pharmacodynamics of Efmarodocokin Alfa, a Variably Glycosylated Fusion Protein.唾液酸介导的内皮细胞和肝脏摄取：一种基于机制的数学模型，阐明了可变糖基化融合蛋白 Efmarodocokin Alfa 的复杂药代动力学和药效动力学。
J Pharm Sci. 2024 Jul;113(7):1975-1986. doi: 10.1016/j.xphs.2024.03.016. Epub 2024 Mar 30.
6
Model-Informed Drug Development of a Sustained Release Formulation of Flucytosine in the Treatment of Cryptococcal Meningitis: A Case Study Using Physiologically Based Pharmacokinetic Modeling.基于模型的氟胞嘧啶缓释制剂在隐球菌性脑膜炎治疗中的药物研发：一项使用生理药代动力学模型的案例研究
CPT Pharmacometrics Syst Pharmacol. 2025 Apr;14(4):651-657. doi: 10.1002/psp4.13309. Epub 2025 Feb 25.
7
Advances in Physiologically Based Pharmacokinetic (PBPK) Modeling and its Regulatory Utility to Support Oral Drug Product Development and Harmonization.基于生理的药代动力学（PBPK）模型的进展及其在支持口服药物产品开发与协调方面的监管效用。
Pharm Res. 2025 Mar 28. doi: 10.1007/s11095-025-03849-9.
8
Evaluating the Impact of AI-Based Model-Informed Drug Development (MIDD): A Comparative Review.评估基于人工智能的模型驱动药物研发（MIDD）的影响：一项比较性综述。
AAPS J. 2025 Jun 2;27(4):102. doi: 10.1208/s12248-025-01075-0.
9
The dawn of a new era: can machine learning and large language models reshape QSP modeling?新时代的曙光：机器学习和大语言模型能否重塑定量系统药理学建模？
J Pharmacokinet Pharmacodyn. 2025 Jun 16;52(4):36. doi: 10.1007/s10928-025-09984-5.
10
Simultaneous Estimation of fm and F Values Directly from Clinical Drug-Drug Interaction Study Data.直接从临床药物相互作用研究数据中同时估算fm和F值。
AAPS J. 2025 Apr 29;27(4):83. doi: 10.1208/s12248-025-01064-3.
本文引用的文献
1
High-performance PBPK model for predicting CYP3A4 induction-mediated drug interactions: a refined and validated approach.用于预测CYP3A4诱导介导的药物相互作用的高性能PBPK模型：一种优化和验证的方法。
Front Pharmacol. 2025 Feb 26;16:1521068. doi: 10.3389/fphar.2025.1521068. eCollection 2025.
2
Translational PK/PD framework for antibody-drug conjugates to inform drug discovery and development.用于指导抗体药物偶联物药物发现与开发的转化性药代动力学/药效学框架。
Xenobiotica. 2024 Aug;54(8):543-551. doi: 10.1080/00498254.2024.2351044. Epub 2024 Sep 27.
3
In vitro PK/PD modeling of tyrosine kinase inhibitors in non-small cell lung cancer cell lines.在非小细胞肺癌细胞系中酪氨酸激酶抑制剂的体外 PK/PD 模型研究。
Clin Transl Sci. 2024 Mar;17(3):e13714. doi: 10.1111/cts.13714.
4
Model-Based Virtual PK/PD Exploration and Machine Learning Approach to Define PK Drivers in Early Drug Discovery.基于模型的虚拟 PK/PD 探索和机器学习方法在早期药物发现中定义 PK 驱动因素。
J Med Chem. 2024 Mar 14;67(5):3727-3740. doi: 10.1021/acs.jmedchem.3c02169. Epub 2024 Feb 20.
5
PBPK/PD Modeling of Nifedipine for Precision Medicine in Pregnant Women: Enhancing Clinical Decision-Making for Optimal Drug Therapy.硝苯地平用于孕妇精准医学的 PBPK/PD 模型：增强临床决策以实现最佳药物治疗。
Pharm Res. 2024 Jan;41(1):63-75. doi: 10.1007/s11095-023-03638-2. Epub 2023 Dec 4.
6
Enhancing drug-drug Interaction Prediction by Integrating Physiologically-Based Pharmacokinetic Model with Fraction Metabolized by CYP3A4.通过整合基于生理的药代动力学模型与CYP3A4代谢分数来增强药物相互作用预测
Expert Opin Drug Metab Toxicol. 2023 Jul-Dec;19(10):721-731. doi: 10.1080/17425255.2023.2263358. Epub 2023 Oct 27.
7
Mechanism-Based Pharmacokinetic Model for the Deglycosylation Kinetics of 20(S)-Ginsenosides Rh2.基于机制的20(S)-人参皂苷Rh2去糖基化动力学的药代动力学模型
Front Pharmacol. 2022 May 25;13:804377. doi: 10.3389/fphar.2022.804377. eCollection 2022.
8
Predicting the Drug-Drug Interaction Mediated by CYP3A4 Inhibition: Method Development and Performance Evaluation.预测由 CYP3A4 抑制介导的药物-药物相互作用：方法开发和性能评估。
AAPS J. 2021 Dec 10;24(1):12. doi: 10.1208/s12248-021-00659-w.
9
Evaluation of Generic Methods to Predict Human Pharmacokinetics Using Physiologically Based Pharmacokinetic Model for Early Drug Discovery of Tyrosine Kinase Inhibitors.使用基于生理学的药代动力学模型预测酪氨酸激酶抑制剂早期药物发现中人体药代动力学的通用方法评估。
Eur J Drug Metab Pharmacokinet. 2019 Feb;44(1):121-132. doi: 10.1007/s13318-018-0496-4.
Zotero 插件